Suspected fake Ozempic causes hypoglycemia in 11 in Lebanon
Send a link to a friend
[November 29, 2023]
By Patrick Wingrove
(Reuters) -Eleven people suffered bouts of dangerously low blood sugar
in Lebanon this year, one of whom required hospitalization, after
injecting suspected fake versions of Novo Nordisk's diabetes drug
Ozempic, according Lebanese health officials.
A director for the Lebanese Ministry of Public Health, Rita Karam, said
officials suspected the drugs were fake after discovering the doses were
different from the ones calibrated for authentic Ozempic injector pens.
Explosive demand for Ozempic and other drugs used for weight loss,
including Eli Lilly's Mounjaro and Novo's Wegovy, is fueling a global
surge in counterfeit versions, Reuters interviews with law enforcement,
anti-counterfeiting and public health officials showed last month.
Counterfeit Ozempic has already been found in at least 17 countries,
including the UK, Germany, Egypt and Russia. Several have issued
warnings to pharmacies and consumers to be vigilant about counterfeits,
since it is not clear what they actually contain.
![](http://archives.lincolndailynews.com/2023/Nov/29/images/ads/current/castlemanor_sda_FINANCIAL_2017.png)
Karam said the ministry had begun investigations into the 11 cases, but
that the source and batch numbers of the drugs in question had not been
identified in most, which made it hard to determine what the victims may
have taken.
Three of the people who took the suspected fake Ozempic did so to
control their diabetes, while four took it for weight management, Karam
said. The other four injected the drug for an 'unspecified indication.'
People with diabetes need to closely manage their blood sugar, which can
be done with a variety of medicines including Ozempic. When blood sugar,
or glucose level, gets too low they can suffer hypoglycemia, with
symptoms that may include headaches or dizziness and can progress to a
loss of consciousness or seizures.
Lebanon's Ministry of Public Health issued two recalls related to
Ozempic in January 2023, according to its website. No cases of
potentially counterfeit Ozempic were reported in Lebanon in 2022, Karam
said.
Novo Nordisk said it investigates and reports every counterfeit case it
finds to local authorities, and that it has created a guide for
healthcare providers in the Middle East to show how to spot fake drugs.
[to top of second column]
|
![](../images/112923PIX/health19.jpg)
A box of Ozempic and contents sit on a table in Dudley, North
Tyneside, Britain, October 31, 2023. REUTERS/Lee Smith/File Photo
![](http://archives.lincolndailynews.com/2023/Nov/29/images/ads/current/graue_lda_preowned_112023.jpg) More than a quarter of Lebanese
adults are obese, according to 2017 figures from the World Obesity
Federation. Obesity has been closely linked with type 2 diabetes, by
far the most common form of the disease.
Data from the International Diabetes Federation showed that almost
9% of adults in Lebanon had diabetes in 2021, compared to nearly 14%
in the United States.
Karam said Ozempic is neither purchased nor provided by the Ministry
of Public Health.
Wegovy, Novo Nordisk’s weight-loss drug with the same active
ingredient - semaglutide - as Ozempic, was shown to help patients
lose an average of 15% of their weight in a late-stage trial.
The scramble for supplies of the powerful pound-shedding molecule
has led to shortages of Ozempic in several countries including
Britain, Germany, Belgium and the United States.
A source familiar with anti-counterfeiting efforts told Reuters last
month that markets where sales of fake weight-loss drugs were most
prevalent included Lebanon and other countries in the Middle East.
Several people have been hospitalized in Austria for hypoglycemia
after taking potentially fake versions of Ozempic. The health safety
regulator there said the side effects indicated the product
contained insulin instead of semaglutide.
Last month, Belgium’s drug regulator said it had seized counterfeit
versions of Ozempic in which the injector pens were confirmed to
contain insulin.
(Reporting by Patrick Wingrove; Editing by Caroline Humer and Bill
Berkrot)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
![](http://archives.lincolndailynews.com/2023/Nov/29/images/ads/current/culligan_sda_HFH_2023.png) |